Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003)

Conditions: Prostate Cancer Metastatic Interventions: Drug: MK-5684; Drug: Abiraterone acetate; Drug: Enzalutamide; Drug: Hydrocortisone; Drug: Fludrocortisone acetate; Drug: Prednisone; Drug: Dexamethasone Sponsors: Merck Sharp& Dohme LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06136624

Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials